Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer: A Phase 1/2 Open-label Nonrandomized Clinical Trial

IMPORTANCE: Metastatic non–small cell lung cancer (mNSCLC) with EGFR exon 20 insertion (EGFRex20ins) mutations is associated with a poor prognosis. Mobocertinib is an oral tyrosine kinase inhibitor designed to selectively target EGFRex20ins mutations. OBJECTIVE: To evaluate treatment outcomes and sa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Caicun, Ramalingam, Suresh S., Kim, Tae Min, Kim, Sang-We, Yang, James Chih-Hsin, Riely, Gregory J., Mekhail, Tarek, Nguyen, Danny, Garcia Campelo, Maria R., Felip, Enriqueta, Vincent, Sylvie, Jin, Shu, Griffin, Celina, Bunn, Veronica, Lin, Jianchang, Lin, Huamao M., Mehta, Minal, Jänne, Pasi A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517885/
https://www.ncbi.nlm.nih.gov/pubmed/34647988
http://dx.doi.org/10.1001/jamaoncol.2021.4761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517885/
https://www.ncbi.nlm.nih.gov/pubmed/34647988
http://dx.doi.org/10.1001/jamaoncol.2021.4761

Ejemplares similares